Although lacking direct clinical evidence, empowering blood-derived cells to accelerate tau clearance may represent a potential AD treatment [37], a strategy jeopardized by the role of neuroinflammation in fostering neurodegeneration [24,73,74,75], which is perhaps linked to disease progression [62]. Here, MAPT is linked to Alzheimer disease.